Therapies for RYR1-Related Myopathies: Where We Stand and the Perspectives-Reference-Cited by-同舟云学术

Therapies for RYR1-Related Myopathies: Where We Stand and the Perspectives

Published:2022-01 Issue:1 Volume:28 Page:15-25
ISSN:1381-6128
Container-title:Current Pharmaceutical Design
language:en
Short-container-title:CPD

Author:

Beaufils Mathilde¹,Travard Lauriane¹,Rendu John¹,Marty Isabelle¹^ORCID

Affiliation:

1. Grenoble Institute Neurosciences, University Grenoble Alpes, INSERM, U1216, CHU Grenoble Alpes, Grenoble,France

Abstract

: RyR1-related myopathies are a family of genetic neuromuscular diseases due to mutations in the RYR1 gene. No treatment exists for any of these myopathies today, which could change in the coming years with the growing number of studies dedicated to the pre-clinical assessment of various approaches, from pharmacological to gene therapy strategies, using the numerous models developed up to now. In addition, the first clinical trials for these rare diseases have just been completed or are being launched. We review the most recent results obtained for the treatment of RyR1-related myopathies, and, in view of the progress in therapeutic development for other myopathies, we discuss the possible future therapeutic perspectives for RyR1-related myopathies.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology

Reference87 articles.

1. Dulhunty AF; Beard NA; Casarotto MG; Recent advances in understanding the ryanodine receptor calcium release channels and their role in calcium signalling. F1000Res F1000 Faculty Rev-1851.2018,7

2. Meissner G.; Regulation of Ryanodine Receptor Ion Channels Through Posttranslational Modifications. Curr Top Membr 2010,66,91-113

3. Mori F.; Fukaya M.; Abe H.; Wakabayashi K.; Watanabe M.; Developmental changes in expression of the three ryanodine receptor mRNAs in the mouse brain. Neurosci Lett 2000,285(1),57-60

4. Pehlivan D.; Bayram Y.; Gunes N.; Coban Akdemir Z.; Shukla A.; Bierhals T.; Tabakci B.; Sahin Y.; Gezdirici A.; Fatih J.M.; Gulec E.Y.; Yesil G.; Punetha J.; Ocak Z.; Grochowski C.M.; Karaca E.; Albayrak H.M.; Radhakrishnan P.; Erdem H.B.; Sahin I.; Yildirim T.; Bayhan I.A.; Bursali A.; Elmas M.; Yuksel Z.; Ozdemir O.; Silan F.; Yildiz O.; Yesilbas O.; Isikay S.; Balta B.; Gu S.; Jhangiani S.N.; Doddapaneni H.; Hu J.; Muzny D.M.; Boerwinkle E.; Gibbs R.A.; Tsiakas K.; Hempel M.; Girisha K.M.; Gul D.; Posey J.E.; Elcioglu N.H.; Tuysuz B.; Lupski J.R.; The genomics of arthrogryposis, a complex trait: Candidate genes and further evidence for oligogenic inheritance. Am J Hum Genet 2019,105(1),132-150

5. Bertocchini F.; Ovitt C.E.; Conti A.; Barone V.; Schöler H.R.; Bottinelli R.; Reggiani C.; Sorrentino V.; Requirement for the ryanodine receptor type 3 for efficient contraction in neonatal skeletal muscles. EMBO J 1997,16(23),6956-6963

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functional benefit of CRISPR-Cas9-induced allele deletion for RYR1 dominant mutation;Molecular Therapy - Nucleic Acids;2024-09

2. Myopathic manifestations across the adult lifespan of patients with malignant hyperthermia susceptibility: a narrative review;British Journal of Anaesthesia;2024-08

3. Targeted gene delivery through receptors with lipid nanoparticles;Journal of Drug Delivery Science and Technology;2024-03

4. Functional benefit of CRISPR/Cas9-induced allele deletion forRYR1dominant mutation;2024-01-25

5. Generation of two induced pluripotent stem cell lines from a 33-year-old central core disease patient with a heterozygous dominant c.14145_14156delCTACTGGGACA (p.Asn4715_Asp4718del) deletion in the RYR1 gene;Stem Cell Research;2023-12